ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 18 No. 2 (2025), LYMPHOID TUMORS
Vol. 18 No. 2 (2025)
LYMPHOID TUMORS

Options for Program Chemotherapy and Their Outcomes in Patients with Newly Diagnosed Mantle Cell Lymphoma Based on the Data from a Single Center

Published 01.04.2025
Ulyana Gordeevna Koshkina
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0009-0000-1023-5426
G.S. Tumyan
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993
https://orcid.org/0000-0002-5771-4413
A.A. Semenova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0003-4951-3053
M.Yu. Kichigina
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0002-2715-2528
I.Z. Zavodnova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0001-6674-8634
D.N. Tupitsyna
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0009-0003-4830-1160
E.V. Paramonova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0009-0008-7886-7671
A.S. Antipova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0002-1731-8336
V.O. Shpirko
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0002-2300-0332
Yu.I. Klyuchagina
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0003-2748-9208
S.F. Ramazanova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0009-0008-7084-0060
A.V. Arakelyan
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435
https://orcid.org/0000-0003-4911-0959
G.D. Petrova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0003-4207-2822
O.Yu. Baranova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0002-0202-8176
N.A. Kupryshina
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0001-8509-0954
E.A. Osmanov
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0002-3067-1601
2025-2
PDF_2025-18-2-121-133 (Russian)

Keywords

mantle cell lymphoma
clinical features
diagnosis
treatment

How to Cite

Koshkina U.G., Tumyan G.S., Semenova A.A., Kichigina M.Y., Zavodnova I.Z., Tupitsyna D.N., Paramonova E.V., Antipova A.S., Shpirko V.O., Klyuchagina Y.I., Ramazanova S.F., Arakelyan A.V., Petrova G.D., Baranova O.Y., Kupryshina N.A., Osmanov E.A. Options for Program Chemotherapy and Their Outcomes in Patients with Newly Diagnosed Mantle Cell Lymphoma Based on the Data from a Single Center. Clinical Oncohematology. 2025;(2):121–133. doi:10.21320/2025-18-2-121-133.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Statistics

Annotation views: 7
PDF_2025-18-2-121-133 (Russian) downloads: 16

Keywords

Abstract

AIM. To assess the clinical characteristics and efficacy of chemotherapy for patients with newly diagnosed mantle cell lymphoma (MCL) based on the data from a single center.

MATERIALS & METHODS. The study enrolled 60 MCL patients treated at the NN Blokhin National Medical Cancer Research Center from 2008 to 2024. The patients were 37–79 years of age (median 58 years); there were 22 women and 38 men. According to MIPI, there were 18 (30 %) low risk, 22 (37 %) intermediate risk, and 20 (33 %) high risk patients. Intensified regimens with high-dose cytarabine were administered to 31 (52 %) patients, whereas standard non-intensified R-CHOP, R-B, R-BAC and similar regimens were used in 29 (48 %) patients. Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 18 (30 %) patients after completing 6 cycles of induction immunochemotherapy. Maintenance rituximab therapy was assigned to 36 (60 %) patients. Ibrutinib, one of Bruton’s tyrosine kinase inhibitors, was added to basic immunochemotherapy in 11 (18 %) patients.

RESULTS. The 3-year progression-free survival (PFS) of the recipients of intensified regimens with high-dose cytarabine was 73 % vs. 54 % (p < 0.05) shown by the recipients of the above listed standard non-intensified treatment protocols. The 3-year PFS of elderly recipients of bendamustine-based treatment was 64 % vs. 25 % shown by the patients treated with R-CHOP/R-CHOP-like regiments (p = 0.05). The 3-year PFS of recipients and non-recipients of maintenance rituximab therapy was 86 % and 33 %, respectively (p = 0.001). In the groups of recipients and non-recipients of auto-HSCT, it was reported to be 76 % and 56 % (p = 0.05). In the total group (n = 60), with the follow-up median of 36 months, the 3-year PFS was 64 % (median 54 months), and the 3-year OS was 80 % (median 84 months). The 3-year PFS rates in MCL patients varied considerably at different historic stages and were 42 % during the period from 2008 to 2017 and 86 % from 2018 to 2024 (p = 0.02).

CONCLUSION. The present study covers the period of 16 years characterized by changing approaches to MCL treatment. The 3-year PFS rate of 86 % in the period of 2018–2024 increased nearly twofold compared to 2008–2017. Intensified program MCL first-line therapy with high-dose cytarabine significantly improves the long-term outcomes as opposed to standard immunochemotherapy (R-CHOP, R-B, etc.). For elderly MCL patients, bendamustine-based regimens appear to be most effective. Irrespective of patient’s age, it should be recognized that ibrutinib added to basic MCL chemotherapy holds the most promise. Maintenance rituximab therapy is a must in program treatment. Consolidation auto-HSCT performed after basic immunochemotherapy is associated with higher rates of long-term survival. The present study yielded results comparable to international data and showing a high reproducibility in real-world clinical practice.

PDF_2025-18-2-121-133 (Russian)

References

  1. 1. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–59. doi: 10.3322/caac.21357.
  2. 2. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–8. doi: 10.1002/cncr.23608.
  3. 3. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. WHO classification of tumours series, 5th ed. Vol. 11. Lyon: IARC Press; 2022.
  4. 4. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33(1):7–20. doi: 10.1053/hupa.2002.30221.
  5. 5. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408–18. doi: 10.1158/0008-5472.
  6. 6. Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121–7. doi: 10.3324/haematol.2010.036277.
  7. 7. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307–16. doi: 10.1158/0008-5472.
  8. 8. Jain P, Dreyling M, Seymour JF, Wang M. High-Risk Mantle Cell Lymphoma: Definition, Current Challenges and Management. J Clin Oncol. 2020;38(36):4302–16. doi: 10.1200/JCO.20.02287.
  9. 9. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first line treatment for patient with indolent and mantle cell lymphomas: an open-label, multicenter, randomized, phase 3 non inferiority trial. Lancet. 2013;381(9873):1203–10. doi: 10.1016/S0140-6736(12)61763-2.
  10. 10. Flinn IW, Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52. doi: 10.1182/blood-2013-11-531327.
  11. 11. Villa D, Sehn LH, Savage KJ, et al. Bendamustine and rituximab as induction therapy in both transplant‐eligible and ‐ineligible patients with mantle cell lymphoma. Blood Adv. 2020;4(15):3486–94. doi: 10.1182/bloodadvances.2020002068.
  12. 12. Rampotas A, Wilson MR, Lomas O, et al. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. Br J Haematol. 2021;194(2):365–77. doi: 10.1111/bjh.17513.
  13. 13. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. Engl J Med. 2015;372(10):944–53. doi: 10.1056/NEJMoa1412096.46.
  14. 14. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45. doi: 10.1182/blood-2015-03-635326.
  15. 15. Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211–e214. doi: 10.3324/haematol.2018.205229.
  16. 16. Wang M, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022;386(26):2482–94. doi: 10.1056/NEJMoa2201817.
  17. 17. Hernandez-Rivas J, Zinzani P, Jerkeman M, et al. Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting. 64th Annual Meeting and Exposition of the American Society of Hematology (ASH). New Orleans, December 10–13, 2022. Poster 1584.
  18. 18. Hernandez-Rivas J, Zinzani P, Jerkeman M, et al. Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting. Blood. 2022;140(Suppl 1):3648–50. doi: 10.1182/blood-2022-158259.
  19. 19. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–67. doi: 10.1016/S0140-6736(17)33108-2.
  20. 20. Song Y, Zhou K, Zou D, et al. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase. Clin Cancer Res. 2020;26(16):4216–24. doi: 10.1158/1078-0432.CCR-19-3703.
  21. 21. Wang MM, Mayer J, Belada D, et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled echo trial. EHA Library. 2024;4136515: Abstract LB3439.
  22. 22. Jain P, Zhao S, Lee HJ, et al. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022;40(2):202–12. doi: 10.1200/JCO.21.01797.
  23. 23. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv62–iv71. doi: 10.1093/annonc/mdx223.
  24. 24. Hermine O, Jiang L, Walewski J, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2023;41(3):479–84. doi: 10.1200/JCO.22.01780.
  25. 25. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60. doi: 10.1056/NEJMoa1701769.
  26. 26. Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8. doi: 10.1111/bjh.14241.
  27. 27. Chihara D, Cheah CY, Jason R, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer. Br J Haematol. 2016;172(1):80–8. doi: 10.1111/bjh.13796.
  28. 28. Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75. doi: 10.1016/S0140-6736(16)00739-X.
  29. 29. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60. doi: 10.1056/NEJMoa1701769.
  30. 30. Wang ML, Jain P, Zhao S, et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022;23(3):406–15. doi: 10.1016/S1470-2045(21)00638-0.
  31. 31. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403(10441):2293–306. doi: 10.1016/S0140-6736(24)00184-3.
  32. 32. Dreyling M, Doorduijn J, Giné E, et al. Role of Autologous Stem Cell Transplantation in the Context of IR-B Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network. ASH; 2024. Abstract 240.
  33. 33. Gouill SL, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137(7):877–87. doi: 10.1182/blood.2020008727.
  34. 34. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018;378(13):1211–23. doi: 10.1056/NEJMoa1715519.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2025 Clinical Oncohematology